Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says
LONDON, Nov 19 (Reuters) - The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numerator said on Thursday.
UK households with at least one GLP‑1 user spent more than £1 billion less on groceries than expected in the year after adoption compared with households without a GLP-1 user, Worldpanel said
The proportion of British households with a user of GLP-1 drugs, such as Eli Lilly's LLY.N Mounjaro or Novo Nordisk's NOVOb.CO Wegovy, has risen from 6.3% in February this year to 8.5% in August
Growth is accelerating. In the six-month period, user numbers of GLP-1 injections and pills rose almost as much as they did in the whole of the previous year
Despite regulatory approval only coming in June, pills, account for 11.2% of UK GLP-1 users
Men are also driving growth, making up 32% of users, up from 23% in February
Worldpanel by Numerator is a global consumer data company. Its survey data of what British households buy drew from a total sample of 9,629
The £1 billion figure of displaced spending from Britain's grocery market is equivalent to £389 a year displaced from each user households' shopping baskets.
Spending on alcohol and crisps among users has fallen 15% more than in non-user households
In contrast, easy, portion-controlled options are gaining ground. Volume sales of frozen ready meals have risen 30% among users
Worldpanel said its estimates suggested that GLP-1 usage was set to surpass 10% of British households in 2027
($1 = 0.7578 pounds)